Ogino H, Iwamatsu K, Katano K, Nakabayashi S, Yoshida T, Shibahara S, Tsuruoka T, Inouye S, Kondo S
Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd., Yokohama, Japan.
J Antibiot (Tokyo). 1990 Feb;43(2):189-98. doi: 10.7164/antibiotics.43.189.
A practical synthetic method for large scale production of MT0703, (6R,7R)-7-[(RS)-2-(2-aminothiazol-4-yl)-2-(1,5-dihydroxy-4-pyridon e-2- carboxamido)acetamido]-3-[[1-(2-hydroxyethyl)pyridinium-4- yl]thiomethyl]ceph-3-em-4-carboxylate, was established. Its two diastereomers on configuration of the aminothiazolylglycyl moiety were synthesized using chemico-enzymatic method. The S-isomer of MT0703 was found to be more active against Gram-positive and Gram-negative bacteria including beta-lactamase-producing strains than the R-isomer.
建立了一种用于大规模生产MT0703((6R,7R)-7-[(RS)-2-(2-氨基噻唑-4-基)-2-(1,5-二羟基-4-吡啶酮-2-羧酰胺基)乙酰胺基]-3-[[1-(2-羟乙基)吡啶鎓-4-基]硫代甲基]头孢-3-烯-4-羧酸酯)的实用合成方法。采用化学酶法合成了其在氨基噻唑基甘氨酰部分构型上的两种非对映异构体。发现MT0703的S-异构体对革兰氏阳性菌和革兰氏阴性菌(包括产β-内酰胺酶菌株)的活性比R-异构体更高。